MuSK Myasthenia Gravis-Potential Pathomechanisms and Treatment Directed against Specific Targets
Source : https://pubmed.ncbi.nlm.nih.gov/38534400/
Myasthenia gravis (MG) is an autoimmune disease in which autoantibodies target structures within the neuromuscular junction, affecting neuromuscular transmission. Muscle-specific tyrosine kinase receptor-associated MG (MuSK-MG) is a rare, often more...
MuSK-MG, a severe subtype of myasthenia gravis, involves distinct pathomechanisms and requires specialized treatments; ongoing research aims to improve understanding and therapy options.
The Role of Thymoma and Thymic Hyperplasia as Prognostic Risk Factors for Secondary Generalisation in Adults with Ocular Myasthenia Gravis: A Systematic Narrative Review
Source : https://pubmed.ncbi.nlm.nih.gov/38046270/
This review provides evidence for the consideration of thymectomy early after thymomatous OMG diagnosis to prevent GMG conversion. As the review did not collect enough evidence to support the influence...
This review provides evidence for the consideration of thymectomy early after thymomatous OMG diagnosis to prevent GMG conversion. As the review did not collect enough evidence to support the influence of thymic hyperplasia on OMG conversion, further research is required.
Ravulizumab in Myasthenia Gravis: A Review of the Current Evidence
Source : https://pubmed.ncbi.nlm.nih.gov/38059203/
The terminal complement C5 inhibitor ravulizumab was engineered from the humanized monoclonal antibody eculizumab to have an extended half-life and duration of action. It binds to human terminal complement protein...
Ravulizumab, a terminal complement C5 inhibitor, demonstrated rapid and sustained efficacy with a favorable safety profile in treating anti-acetylcholine receptor antibody-positive generalized myasthenia gravis, supported by its extended dosing interval and targeted mechanism of action.
Zilucoplan: First Approval
Source : https://pubmed.ncbi.nlm.nih.gov/38093160/
Zilucoplan (Zilbrysq ® ) is a subcutaneously administered macrocyclic peptide inhibitor of complement component 5 (C5 inhibitor) being developed by UCB for the treatment of generalised myasthenia gravis (gMG). Zilucoplan...
Zilucoplan (Zilbrysq®), a C5 inhibitor, has received approvals in Japan, the USA, and the EU for treating generalized myasthenia gravis in adults who are anti-AChR antibody positive and have inadequate response to other therapies, marking significant milestones in its development.
Eculizumab in Adolescent Patients With Refractory Generalized Myasthenia Gravis: A Phase 3, Open-Label, Multicenter Study
Source : https://pubmed.ncbi.nlm.nih.gov/38810600/
Eculizumab was effective in reducing disease burden and was well tolerated in adolescents with refractory AChR antibody-positive gMG.
Eculizumab was effective in reducing disease burden and was well tolerated in adolescents with refractory AChR antibody-positive gMG.